Regencell Bioscience (NASDAQ:RGC) Stock Price Up 14.6% - Time to Buy?

Key Points

• 14.6% surge: RGC jumped as high as $32.78 and last traded at $31.00 on Tuesday, a sharp move that occurred on about 295,348 shares (down ~59% from average) and leaves the stock well above its 50‑day ($16.35) and 200‑day ($15.92) moving averages.
• Analyst sentiment is negative: Weiss Ratings reiterated a "sell (e+)" rating and the stock's average analyst rating on MarketBeat is listed as Sell.
• Minimal institutional ownership despite recent buys: Institutions own only about 0.13% of the stock, though several firms (including Geode, Squarepoint, BNP Paribas, XTX and Y Intercept) recently established or increased positions—Geode boosted its stake by 5,637.5%.

Regencell Bioscience Holdings Limited (NASDAQ:RGC - Get Free Report) shot up 14.6% during trading on Tuesday . The company traded as high as $32.78 and last traded at $31.00. 295,348 shares were traded during trading, a decline of 59% from the average session volume of 725,313 shares. The stock had previously closed at $27.04.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of Regencell Bioscience in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of "Sell".

Regencell Bioscience Stock Performance

The firm's 50 day moving average price is $16.35 and its two-hundred day moving average price is $15.92.

Institutional Trading of Regencell Bioscience

Several institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its holdings in shares of Regencell Bioscience by 5,637.5% during the second quarter. Geode Capital Management LLC now owns 391,066 shares of the company's stock worth $6,664,000 after buying an additional 384,250 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in Regencell Bioscience during the second quarter worth approximately $1,701,000. BNP Paribas Financial Markets bought a new position in Regencell Bioscience during the 2nd quarter worth $768,000. XTX Topco Ltd bought a new stake in shares of Regencell Bioscience during the 3rd quarter valued at $598,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Regencell Bioscience during the 2nd quarter worth $222,000. 0.13% of the stock is currently owned by institutional investors.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.